Detalles de la búsqueda
1.
Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study.
Blood
; 143(8): 713-720, 2024 Feb 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38085846
2.
C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement.
Mol Ther
; 32(4): 1061-1079, 2024 Apr 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38382529
3.
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.
Blood
; 140(9): 980-991, 2022 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35687757
4.
Anti-C1s humanized monoclonal antibody SAR445088: A classical pathway complement inhibitor specific for the active form of C1s.
Clin Immunol
; 251: 109629, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37149117
5.
Local-field approximation of homonuclear dipolar interactions in 7Li-NMR: density-matrix calculations and random-walk simulations tested by echo experiments on borate glasses.
Solid State Nucl Magn Reson
; 59-60: 8-19, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24593983
6.
C1s targeting antibodies inhibit the growth of cutaneous squamous carcinoma cells.
Sci Rep
; 14(1): 13465, 2024 06 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38866870
7.
Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases.
Blood
; 118(17): 4705-13, 2011 Oct 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-21860027
8.
First-in-human study with SAR445088: A novel selective classical complement pathway inhibitor.
Clin Transl Sci
; 16(4): 673-685, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36661084
9.
SAR443809: a selective inhibitor of the complement alternative pathway, targeting complement factor Bb.
Blood Adv
; 7(16): 4258-4268, 2023 08 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36897252
10.
NMR and conductivity studies of the mixed glass former effect in lithium borophosphate glasses.
J Chem Phys
; 137(12): 124507, 2012 Sep 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-23020343
11.
Development and Optimization of Bifunctional Fusion Proteins to Locally Modulate Complement Activation in Diseased Tissue.
Front Immunol
; 13: 869725, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35784298
12.
Classical Complement Pathway Inhibition in a "Human-On-A-Chip" Model of Autoimmune Demyelinating Neuropathies.
Adv Ther (Weinh)
; 5(6)2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36211621
13.
The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models.
Mol Immunol
; 105: 150-164, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30513451
14.
High-resolution footprinting of sequence-specific protein-DNA contacts.
Nat Biotechnol
; 20(2): 183-6, 2002 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-11821865
15.
Global View on Rare Diseases: A Mini Review.
Curr Med Chem
; 24(29): 3153-3158, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28494745
16.
Positive and Negative Mixed Glass Former Effects in Sodium Borosilicate and Borophosphate Glasses Studied by (23)Na NMR.
J Phys Chem B
; 120(19): 4482-95, 2016 05 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-27092392
17.
5-amino-2'-deoxyuridine, a novel thymidine analogue for high-resolution footprinting of protein-DNA complexes.
Org Lett
; 4(22): 3867-9, 2002 Oct 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-12599479
18.
Synthesis of cyclic pyranopterin monophosphate, a biosynthetic intermediate in the molybdenum cofactor pathway.
J Med Chem
; 56(4): 1730-8, 2013 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-23384403
19.
Solution structure of TT30, a novel complement therapeutic agent, provides insight into its joint binding to complement C3b and C3d.
J Mol Biol
; 418(3-4): 248-63, 2012 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-22387467
20.
Delineation of the complement receptor type 2-C3d complex by site-directed mutagenesis and molecular docking.
J Mol Biol
; 404(4): 697-710, 2010 Dec 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-20951140